Placebo Effects Investigated by Different Experimental Designs
- Conditions
- BaselineCaffeinePlacebo
- Interventions
- Dietary Supplement: CaffeineOther: Placebo
- Registration Number
- NCT04317157
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
This study aims to investigate the neurophysiological mechanisms of placebo perceived as caffeine during a motor task. Central and peripheral measures (i.e. electroencephalography and electromyography) will be assessed.
- Detailed Description
Classical randomized clinical trial (RCT) controlled by a placebo is considered as the gold-standard design when evaluating the efficacy of drugs and interventions, as a given treatment is scientifically sound only if it is superior to placebo. One of strongest threats to placebo is that a double-blinded RCT could not completely neutralize every human consciousness-distorted reality; behavioral aspects such as the belief on a given treatment may directly result in different placebo effects and produce different treatment placebo effect sizes. Any patient may create his/her own expectation on a situation having a chance of 50% placebo vs 50% treatment depending on the available information; beliefs may impact on working mechanism of pharmacological treatments, but also on placebos. One alternative emerged from debates by different scientific fields; the control for the participant's expectancy by using an active substance-perceived placebo. When compared to a traditional double-blinded placebo-controlled RCT design, the placebo-deceived design has the advantage of controlling expectation and anxiety biases in treatments having combined pharmacological and psychological effects, despite some obvious limitation.
Mechanisms underpinning the ergogenic effect of placebos are unclear, but the suggestion is that the expectancy in using an ergogenic treatment/substance leads to psychobiological changes comparable to the actual treatment. A question that arises over RCT designs is how much effect on physical performance can be attributed to the actual substance and how much to the expectancy of receiving the actual substance. This question is relevant, as clinical and exercise settings have used double-blinded placebo-controlled RCT designs to investigate the ergogenic aids effects and mechanisms. However, participants may experience different placebo effect sizes in a double-blinded RCT design. This study will investigate ergogenic placebo effects and mechanisms elicited by double-blinded placebo-controlled RCT and deceived-placebo designs.
This crossover study will investigate two different experimental designs. During the traditional double-blind RCT, participants will be informed that they will be randomly assigned to caffeine and placebo sessions, thereby having 50% placebo chances vs 50% caffeine chances. However, they will receive placebo capsules in both RCT sessions (non-informed substance/received placebo). In contrast, they will be precisely informed about their allocation (either caffeine or placebo trial) in the deceived-placebo design, however they will ingest placebo capsules in both sessions (informed caffeine/received placebo vs informed placebo/received placebo), thereby controlling caffeine pharmacological effects. A true caffeine trial (informed caffeine/received caffeine 6 mg·kg-1) will be performed as a positive control in the last session.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 18
- Healthy subjects
- Must be able to swallow pills
- Must be able to perform isometric knee extension
- Subjects with motor impairments
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Control-Caffeine Caffeine Participants will be informed they are ingesting 6 mg.kg-1 of caffeine \~45 minutes before the trial. Placebo Clinical Trial Placebo Participants will ingest placebo \~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion. Caffeine Clinical Trial Placebo Participants will ingest 6 mg.kg-1 of caffeine \~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion. Placebo-deceived Caffeine Placebo Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine \~45 minutes before the trial. Placebo-deceived Placebo Placebo Participants will be informed they are ingesting placebo \~45 minutes before the trial.
- Primary Outcome Measures
Name Time Method Torque change 30 minutes before the intervention and up to 60 minutes after the intervention Knee extension torque (N∙m) will be recorded during a maximal voluntary contraction through a load cell (EMG System ®, São José dos Campos, Brazil) coupled to a custom-built knee extension chair. Participants will have their torso individually adjusted on a backrest, in a comfortable position, fixed with straps to avoid body movement.
Motor related cortical potential change Throghout the isometric contraction 30 minutes before the intervention and up to 60 minutes after the intervention Will be recorded at Fz, Cz, Pz, C1 and C2 positions (µV) by using an electroencephalogram (EEG); the EEG recorded during the EMG burst (from 2 s before up to 4 s after the EMG onset) will be used to calculate the EEG amplitude (μv) in 4 windows within the muscle contraction such as; readiness potential (-1,5 to 0 s), muscle contraction 1 (0 to 1 s), muscle contraction 2 (1 to 2 s) and recovery (3 to 4 s).
M-wave change 30 minutes before the intervention and up to 60 minutes after the intervention M- and (mV) will be recorded at 10 s intervals through wireless electrodes placed over the vastus lateralis and vastus medialis muscles at rest, being considered as the peak-to-peak amplitude.
H-reflex change 30 minutes before the intervention and up to 60 minutes after the intervention H-reflex (mV) will be recorded at 10 s intervals through wireless electrodes placed over the vastus lateralis and vastus medialis muscles at rest, being considered as the peak-to-peak amplitude.
Rate of force development change 30 minutes before the intervention and up to 60 minutes after the intervention Rate of force development (N∙m/s) will be recorded during a maximal voluntary contraction through a load cell (EMG System ®, São José dos Campos, Brazil) coupled to a custom-built knee extension chair. Participants will have their torso individually adjusted on a backrest, in a comfortable position, fixed with straps to avoid body movement.
Muscle activity change Throughout the exercises performed 30 minutes before the intervention and up to 60 minutes after the intervention Vastus lateralis and vastus medialis muscles electromyography (EMG; (mV) will be assessed throughout both the exercises (maximal voluntary contraction and submaximal isometric voluntary contraction) according to standard recommendation.
V-wave change 30 minutes before the intervention and up to 60 minutes after the intervention V-wave (mV) and V-wave/Mmax (a.u.) will be recorded at 10 s intervals through wireless electrodes placed over the vastus lateralis and vastus medialis muscles at rest, being considered as the peak-to-peak amplitude.
- Secondary Outcome Measures
Name Time Method Ratings o perceived exertion change Throughout the isometric contraction 30 minutes before the intervention and up to 60 minutes after the intervention Ratings of perceived exertion (RPE) will be obtained through a category-ratio (CR-10) Borg scale (u.a.). Participants will be familiarized with the scale anchors having the maximal voluntary contraction test as maximal effort template. The scale range from 0 - 10 reflecting the exerted effort (i.e. 0 for nothing at all and 10 extremely strong effort).
Trial Locations
- Locations (1)
School of Arts, Sciences and Humanities - University of São Paulo
🇧🇷São Paulo, Brazil